267 related articles for article (PubMed ID: 31199450)
1. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.
Li P; Jahnke J; Pettit AR; Wong YN; Doshi JA
JAMA Netw Open; 2019 Jun; 2(6):e195806. PubMed ID: 31199450
[TBL] [Abstract][Full Text] [Related]
2. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
4. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
[TBL] [Abstract][Full Text] [Related]
5. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
Colomba E; Le Teuff G; Eisen T; Stewart GD; Fife K; Larkin J; Biondo A; Pickering L; Srinivasan A; Boyle H; Derosa L; Sternberg CN; Recine F; Ralph C; Saldana C; Barthélémy P; Bernhard JC; Gurney H; Verhoest G; Vauleon E; Bigot P; Berger J; Pfister C; Gravis G; Rodier JM; Culine S; Caty A; Rolland F; Priou F; Escudier B; Albiges L
Eur J Cancer; 2017 Jul; 80():55-62. PubMed ID: 28549248
[TBL] [Abstract][Full Text] [Related]
6. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.
Shek D; Tomlinson B; Brown M; Brunson A; Pan CX; Lara PN
Clin Genitourin Cancer; 2012 Jun; 10(2):93-8. PubMed ID: 22382008
[TBL] [Abstract][Full Text] [Related]
7. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Perez JR; Agarwal N; Vogelzang NJ
Clin Genitourin Cancer; 2017 Aug; 15(4):e573-e582. PubMed ID: 28139444
[TBL] [Abstract][Full Text] [Related]
8. The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database.
Vaishampayan U; Vankayala H; Vigneau FD; Quarshie W; Dickow B; Chalasani S; Schwartz K
Clin Genitourin Cancer; 2014 Apr; 12(2):124-9. PubMed ID: 24225251
[TBL] [Abstract][Full Text] [Related]
9. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain RK; Chahoud J; Spiess PE; Sexton W; Gilbert SM; Manley BJ
JAMA Netw Open; 2021 May; 4(5):e2111329. PubMed ID: 34032854
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
Wagstaff J; Jones R; Hawkins R; Porfiri E; Pickering L; Bahl A; Brown J; Buchan S
Ann Oncol; 2016 Jan; 27(1):159-65. PubMed ID: 26489444
[TBL] [Abstract][Full Text] [Related]
11. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
Conti SL; Thomas IC; Hagedorn JC; Chung BI; Chertow GM; Wagner TH; Brooks JD; Srinivas S; Leppert JT
Int J Cancer; 2014 May; 134(9):2245-52. PubMed ID: 24135850
[TBL] [Abstract][Full Text] [Related]
12. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
Pal SK; Nelson RA; Vogelzang N
PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
15. Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era.
Sierra PS; Cordeiro MD; Albuquerque EV; Bastos DA; Bonadio RC; Sarkis AS; Cavalcante A; Pontes J; Coelho RF; Nahas WC
Clin Genitourin Cancer; 2020 Apr; 18(2):e134-e144. PubMed ID: 31980410
[TBL] [Abstract][Full Text] [Related]
16. Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration.
Aspinall SL; Zhao X; Geraci MC; Good CB; Cunningham FE; Heron BB; Becker D; Lee S; Prasad V;
Cancer Med; 2019 Nov; 8(15):6651-6661. PubMed ID: 31536684
[TBL] [Abstract][Full Text] [Related]
17. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma.
Chakiryan NH; Acevedo AM; Garzotto MA; Chen Y; Liu JJ; Isharwal S; Amling CL; Kopp RP
Urol Oncol; 2020 Jun; 38(6):604.e1-604.e7. PubMed ID: 32241693
[TBL] [Abstract][Full Text] [Related]
19. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
[TBL] [Abstract][Full Text] [Related]
20. Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma.
Tallman JE; Pearce SM; Kuchta K; Helfand BT; Eggener SE
J Urol; 2017 Nov; 198(5):1027-1032. PubMed ID: 28551443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
